EGFR and lung adenocarcinoma: Furthermore, as shown in Table 2, lung adenocarcinoma patients with the distant TNM stage had a significantly lower prevalence of both HPV 16E6/18E6 and EGFR expressions (E6+tEGFR+ vs. E6−tEGFR−, OR [95% CI] = 0.39 [0.16–0.94], p = 0.034).